Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 27;69(12):2119-2126.
doi: 10.1093/cid/ciz131.

Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting

Affiliations

Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting

Mirjam Groger et al. Clin Infect Dis. .

Abstract

Background: Plasmodium ovale curtisi and wallikeri are perceived as relapsing malarial parasites. Contrary to Plasmodium vivax, direct evidence for this hypothesis is scarce. The aim of this prospective study was to characterize the reappearance patterns of ovale parasites.

Methods: P. ovale spp. infected patients were treated with artemether-lumefantrine and followed biweekly for up to 1 year for the detection of reappearing parasitemia. Molecular analysis of reappearing isolates was performed to identify homologous isolates by genotyping and to define cases of relapse following predefined criteria.

Results: At inclusion, 26 participants were positive for P. ovale curtisi and/or P. ovale wallikeri. The median duration of follow-up was 35 weeks. Reappearance of the same P. ovale species was observed in 46% of participants; 61% of P. ovale curtisi and 19% of P. ovale wallikeri infection-free intervals were estimated to end with reappearance by week 32. Based on the predefined criteria, 23% of participants were identified with 1 or 2 relapses, all induced by P. ovale curtisi.

Conclusion: These findings are in line with the currently accepted relapse theory inasmuch as the reappearance of P. ovale curtisi strains following initial blood clearance was conclusively demonstrated. Interestingly, no relapse of P. ovale wallikeri was observed.

Keywords: Plasmodium ovale; Plasmodium ovale curtisi; Plasmodium ovale wallikeri; CERMEL; relapse.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient profile/timeline plot depicting reappearance patterns throughout the observational period. The x-axis shows the time in weeks, the y-axis displays Plasmodium ovale spp. infection as categorical variable (yes/no). For better visibility, infection variables are jittered (no: −0.2 to 0.2; yes: 0.8–1.2). Missing values are represented by gaps.
Figure 2.
Figure 2.
Infection-free intervals until first (quantitative polymerase chain reaction positive) reappearance in weeks of Plasmodium ovale curtisi parasites (A) and Plasmodium ovale wallikeri parasites (B). The unit of interest is participants. + Loss to follow-up; gray area: 95% confidence interval.
Figure 3.
Figure 3.
Infection-free intervals until (quantitative polymerase chain reaction positive) reappearance in weeks for all observed reappearances of Plasmodium ovale curtisi parasites (A) and Plasmodium ovale wallikeri parasites (B). Following drop out due to reappearance, participants are reincluded in the Kaplan-Meier blots. The unit of interest is infection-free time to reappearance. + Loss to follow-up; gray area: 95% confidence interval.
Figure 4.
Figure 4.
Kaplan-Meier blots show time in weeks to first relapse of Plasmodium ovale curtisi measuring participants (A) and all observed relapses of P. ovale curtisi parasites measuring time to relapse (B).
Figure 5.
Figure 5.
Median Joining network of a 624bp section of the nuclear 18S rDNA gene of Plasmodium ovale curtisi, showing the relationships between haplotypes and information on the geographic origin by country. Numbers in the circles indicate the number of individuals sharing the same haplotype, and bars indicate the number of substitutions between haplotypes. Samples are described in detail in Supplementary Table 1 (Rep324_1: Rep324-SCR and D28; Rep 324_2: Rep324-W12).

Comment in

References

    1. Mueller I, Galinski MR, Baird JK, et al. . Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 2009; 9:555–66. - PubMed
    1. Groger M, Fischer HS, Veletzky L, Lalremruata A, Ramharter M. A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria. Malar J 2017; 16:112. - PMC - PubMed
    1. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011; 10:297. - PMC - PubMed
    1. Stephens J. A new malaria parasite of man. Ann Trop Med Parasitol 1922; 16:383–6.
    1. Stephens J, Owen DU. Plasmodium ovale. Ann Trop Med Parasitol 1927; 21:293–302.

Publication types

Substances